Who will benefit more from maintenance therapy of metastatic colorectal cancer?

Whether there is a difference in the efficacy of maintenance treatment for metastatic colorectal cancer (mCRC) between patients who achieve complete response (CR)/partial response (PR) and those with stable disease (SD) after induction treatment is controversial. PubMed, Cochrane Systematic Reviews,...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Mingyi, Fu, Lingyu, Zhang, Jingdong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5844763/
https://www.ncbi.nlm.nih.gov/pubmed/29552327
http://dx.doi.org/10.18632/oncotarget.23549

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5844763/
https://www.ncbi.nlm.nih.gov/pubmed/29552327
http://dx.doi.org/10.18632/oncotarget.23549

Ejemplares similares